Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study.
Purpose: Antibodies against SARS-CoV-2 spike (anti-S) may confer protection against symptomatic COVID-19. Whether their level predicts progression among those with COVID-19 pneumonia remains unclear. Methods: We conducted a retrospective cohort study to assess predictors of anti-S levels and whether...
| Publicado en: | Infection Vol. 52; no. 4; pp. 1499 - 1510 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Aug2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |